Year-to-date money raised in public, private and other financings of biopharma companies.

The top 10 biopharma stock gainers and losers for the week.

The top 10 med-tech stock gainers and losers for the week.

Recovering from a complete response letter (CRL) in 2018, Trevena Inc. resubmitted its NDA for oliceridine, branded Olinvyk. On Aug. 7, the drug received agency approval for managing moderate to severe acute pain in adults when the pain is severe enough to require an I.V. opioid and for patients whose alternative treatments are inadequate. The FDA has now approved a total of 34 new molecular entities (NMEs) so far this year. That total is well ahead of the 18 NMEs that were approved at this time in 2019 even though the FDA suggested back in May that it might have trouble meeting PDUFA dates due to the resources it needed to devote to the COVID-19 pandemic.

A quick look back at top stories.

As the money keeps rolling in, 2020 is certainly a year for the biopharma record books. With a total of $81.26 billion raised through Aug. 6, it is a standout year in every type of financing, hitting all kinds of record highs.

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharma money raised to-date and by quarter in 2020, including public, private and other financings.